Lymphoma, Non-Hodgkin: all 2,043 studies
Page 2 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data CollectionRecruitingNCT06541327
- MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)RecruitingNCT06534437Phase 2
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)RecruitingNCT06533579Phase 1/2
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingNCT06528301Phase 1
- Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLRecruitingNCT06526793Phase 2
- PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyRecruitingNCT06522932Phase 1
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for LymphomaRecruitingNCT06520163Phase 3
- Astragalus for Symptomatic Alleviation in High-grade LymphomaNot yet recruitingNCT06510530Phase 3
- Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront ChemoimmunotherapyRecruitingNCT06510361Phase 2
- A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.RecruitingNCT06497452
- A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRecruitingNCT06494371Phase 1
- A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell LymphomaRecruitingNCT06486051Phase 2
- Study of AXT-1003 in Subjects With Advanced Malignant Tumors.RecruitingNCT06484985Phase 1
- A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLRecruitingNCT06484920Phase 2
- Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological MalignanciesRecruitingNCT06462248Phase 2
- Epcoritamab-CAR T Cells for Large B-cell LymphomasRecruitingNCT06458439Phase 2
- Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to EpcoritamabRecruitingNCT06447376Phase 1
- A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)RecruitingNCT06446128Early Phase 1
- The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic LymphomaNot yet recruitingNCT06434467Phase 3
- This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaNot yet recruitingNCT06427213Phase 2
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsRecruitingNCT06418204
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06395870Phase 1
- Wisconsin Ginseng for Decreasing Cancer Related FatigueRecruitingNCT06395441Phase 3
- A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.RecruitingNCT06393738Phase 1
- A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.RecruitingNCT06383338Phase 1
- Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyRecruitingNCT06357754
- CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+RecruitingNCT06355739Not applicable
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)RecruitingNCT06343311Phase 1/2
- Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHLRecruitingNCT06321289Phase 1/2
- A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT06318884Phase 1
- A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHLNot yet recruitingNCT06314828Phase 1
- A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06313957Phase 1
- Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCLRecruitingNCT06287398Phase 2
- Orelabrutinib in the Treatment of HP-positive Gastric MALT LymphomaRecruitingNCT06228963Phase 2
- A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin LymphomasRecruitingNCT06219356Phase 1
- Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).RecruitingNCT06213636Phase 1/2
- CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 1
- F01 in the Treatment of Relapsed/Refractory Non-hodgkin's LymphomaRecruitingNCT06206902Phase 1
- The Pathogenesis and Prognostic Factors of LymphomaRecruitingNCT06203652
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell LymphomaRecruitingNCT06180174Phase 1
- Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasRecruitingNCT06176690Phase 1
- The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)RecruitingNCT06160362Not applicable
- AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.RecruitingNCT06137144Phase 1/2
- Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology PatientsRecruitingNCT06133426Not applicable
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersRecruitingNCT06119685Phase 1/2
- Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFURecruitingNCT06116110
- Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLRecruitingNCT06104592Phase 2
- CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and LymphomaRecruitingNCT06101381Phase 1/2
- First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive LymphomaNot yet recruitingNCT06097455Early Phase 1
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruitingNCT06090539Phase 1/2
- A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological MalignanciesRecruitingNCT06066203Phase 1/2
- RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT LymphomaNot yet recruitingNCT06064344Not applicable
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
- Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational ResearchNot yet recruitingNCT06049381
- A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell MalignanciesRecruitingNCT06045910Phase 1/2
- Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsRecruitingNCT06043011
- Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic MalignanciesRecruitingNCT06037018Phase 1
- CD79b-19 CAR T Cells in Non-Hodgkin LymphomaRecruitingNCT06026319Phase 1
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.RecruitingNCT06022029Phase 1
- Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin LymphomaRecruitingNCT06021678Phase 1/2
- TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHLRecruitingNCT06014073Phase 1/2
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesRecruitingNCT06013423Phase 2
- A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical PracticeRecruitingNCT06008691
- AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)RecruitingNCT06004011Not applicable
- Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaRecruitingNCT05998642Phase 2
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingNCT05990465Phase 1
- Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's LymphomaNot yet recruitingNCT05979857Early Phase 1
- Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsAvailableNCT05974410
- Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT05967416Phase 1
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Not yet recruitingNCT05923502
- Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma PatientsRecruitingNCT05921812
- Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseRecruitingNCT05907759Phase 2
- A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological TumorsRecruitingNCT05892718Phase 1
- GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic MalignanciesRecruitingNCT05880043Phase 1/2
- A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin LymphomaRecruitingNCT05852028
- Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin LymphomaRecruitingNCT05842707Phase 1/2
- Lifestyle Intervention of Food and Exercise for Lymphoma SurvivorsRecruitingNCT05839210Not applicable
- Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaRecruitingNCT05826535Phase 1/2
- A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHLRecruitingNCT05806099Phase 1/2
- Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's LymphomaRecruitingNCT05805943Phase 1/2
- Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.RecruitingNCT05803395
- Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant DiseasesRecruitingNCT05800210Phase 2
- Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaRecruitingNCT05798897Phase 1
- Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelRecruitingNCT05794958Phase 1
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell MalignanciesRecruitingNCT05780034Phase 1
- Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHLNot yet recruitingNCT05779930Early Phase 1
- A Clinical Study of Injectable IMM0306 in Combination With LenalidomideNot yet recruitingNCT05771883Phase 1/2
- Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT05768529Phase 1/2
- Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic LymphomaRecruitingNCT05745181Phase 2
- Early Detection and Screening of Hematological Malignancies - SANGUINERecruitingNCT05735704
- ThisCART19A for B-NHL Relapsed After Auto-CAR TRecruitingNCT05691153Phase 1
- Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin LymphomaRecruitingNCT05667155Phase 1
- TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid TumorsRecruitingNCT05650580Phase 1
- A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaRecruitingNCT05645107Phase 3
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT05643742Phase 1/2
- TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHLRecruitingNCT05631912Phase 1/2
- A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT05623982Phase 1/2
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaRecruitingNCT05602363Phase 1